|
FPGT expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.44089209850063E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.33146835171283E-15 |
| Normal-vs-Stage2 |
2.24265050974282E-13 |
| Normal-vs-Stage3 |
1.62458935193399E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
9.706200E-01 |
| Stage1-vs-Stage3 |
1.116780E-01 |
| Stage1-vs-Stage4 |
2.007300E-04 |
| Stage2-vs-Stage3 |
2.902600E-01 |
| Stage2-vs-Stage4 |
7.144600E-03 |
| Stage3-vs-Stage4 |
5.352200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
3.55080000000729E-05 |
| Normal-vs-Asian |
1.6269208202857E-12 |
| Caucasian-vs-AfricanAmerican |
6.694000E-02 |
| Caucasian-vs-Asian |
9.863800E-01 |
| AfricanAmerican-vs-Asian |
8.186200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
7.7715611723761E-16 |
| Male-vs-Female |
3.988000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.22124532708767E-15 |
| Normal-vs-Age(41-60Yrs) |
2.22044604925031E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
2.45309999999943E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.275600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.419800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.900600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.805400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.058200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.636200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.211400E-04 |
| Classical-VS-Follicular |
4.301500E-02 |
| Classical-VS-Other |
3.512200E-01 |
| Classical-VS-Normal |
6.21724893790088E-15 |
| Tall-VS-Follicular |
3.88890000000419E-05 |
| Tall-VS-Other |
6.380000E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
1.516650E-01 |
| Follicular-VS-Normal |
1.72606373638473E-12 |
| Other-VS-Normal |
4.72660000028213E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
1.62458935193399E-12 |
| N0-vs-N1 |
4.518300E-03 |
|
|
